KYNTRA BIO, INC. Deferred Revenue
KYNTRA BIO, INC. (KYNB) had Deferred Revenue of $16.93 million as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenueCurrent · last filed 2018-05-09
- 2018-03-31: Deferred Revenue, Current $16.93M.
- 2017-12-31: Deferred Revenue, Current $16.67M; Deferred Revenue, Current as first filed $7.97M.
- 2017-09-30: Deferred Revenue, Current $7.97M.
- 2017-06-30: Deferred Revenue, Current $7.98M.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2018-03-31 | $16.93M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $16.67M 10-Q · filed 2018-05-09 | $7.97M 10-K · filed 2018-02-27 |
| 2017-09-30 | $7.97M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $7.98M 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $7.98M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $7.99M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $7.96M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $15.03M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $12.72M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $12.73M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $12.98M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $13.35M 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $9.06M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $9.22M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |